CL2019000935A1 - Composición farmacéutica, métodos para tratamiento y usos de la misma. - Google Patents

Composición farmacéutica, métodos para tratamiento y usos de la misma.

Info

Publication number
CL2019000935A1
CL2019000935A1 CL2019000935A CL2019000935A CL2019000935A1 CL 2019000935 A1 CL2019000935 A1 CL 2019000935A1 CL 2019000935 A CL2019000935 A CL 2019000935A CL 2019000935 A CL2019000935 A CL 2019000935A CL 2019000935 A1 CL2019000935 A1 CL 2019000935A1
Authority
CL
Chile
Prior art keywords
treatment
methods
pharmaceutical composition
inhibitor
delay
Prior art date
Application number
CL2019000935A
Other languages
English (en)
Spanish (es)
Inventor
Joerg Rippmann
Thomas Klein
Michael Mark
Eric Williams Mayoux
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2019000935A1 publication Critical patent/CL2019000935A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2019000935A 2016-10-19 2019-04-08 Composición farmacéutica, métodos para tratamiento y usos de la misma. CL2019000935A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16194572 2016-10-19

Publications (1)

Publication Number Publication Date
CL2019000935A1 true CL2019000935A1 (es) 2019-08-09

Family

ID=57178303

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000935A CL2019000935A1 (es) 2016-10-19 2019-04-08 Composición farmacéutica, métodos para tratamiento y usos de la misma.

Country Status (14)

Country Link
US (1) US20210212968A1 (OSRAM)
EP (1) EP3528800A1 (OSRAM)
JP (1) JP2019531320A (OSRAM)
KR (1) KR20190070956A (OSRAM)
CN (1) CN109843279A (OSRAM)
AU (1) AU2017344882A1 (OSRAM)
BR (1) BR112019005930A2 (OSRAM)
CA (1) CA3041169A1 (OSRAM)
CL (1) CL2019000935A1 (OSRAM)
EA (1) EA201990951A1 (OSRAM)
IL (1) IL265989A (OSRAM)
MX (1) MX2019004549A (OSRAM)
PH (1) PH12019500845A1 (OSRAM)
WO (1) WO2018073154A1 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190110736A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20190110740A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
MX2021003731A (es) * 2018-09-28 2021-08-05 Acucela Inc Inhibidores de vap-1.
US11787791B2 (en) 2018-09-28 2023-10-17 Acucela Inc. Inhibitors of VAP-1
JP7414230B2 (ja) * 2018-11-09 2024-01-16 国立大学法人 琉球大学 抗血液悪性腫瘍薬
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
TWI835945B (zh) * 2018-12-14 2024-03-21 南韓商柳韓洋行股份有限公司 3,3-二氟烯丙胺化物或其鹽及包含彼的醫藥組合物
TW202039486A (zh) * 2018-12-14 2020-11-01 南韓商柳韓洋行股份有限公司 三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物
EP4028008A4 (en) 2019-09-12 2023-09-13 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
BR112022007974A2 (pt) 2019-10-29 2022-07-12 Eccogene Shanghai Co Ltd Inibidores de ssao e uso dos mesmos
KR20220158022A (ko) * 2020-03-25 2022-11-29 테른스, 인크. 호흡기 장애의 치료
WO2021231644A1 (en) * 2020-05-13 2021-11-18 Terns Pharmaceuticals, Inc. Combination treatment of liver disorders
CN113893256A (zh) * 2020-07-06 2022-01-07 诺未科技（北京）有限公司 化合物或其可药用盐、二聚体或三聚体在制备治疗癌症的药物中的应用
IL300853A (en) 2020-08-25 2023-04-01 Lilly Co Eli Polymorphs of an ssao inhibitor
US20240148767A1 (en) * 2021-03-04 2024-05-09 The Governors Of The University Of Alberta The use of empagliflozin for the treatment of ulcerative colitis and crohn's disease
EP4429665A1 (en) * 2021-11-11 2024-09-18 Terns Pharmaceuticals, Inc. Combination of a ssao inhibitor and thr-beta agonist for use in the treatment of liver disorders
CA3238102A1 (en) * 2021-11-11 2023-05-19 Terns Pharmaceuticals, Inc. Treating liver disorders with an ssao inhibitor

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU229581B1 (en) 1999-08-31 2014-02-28 Kissei Pharmaceutical Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US7053060B2 (en) 2000-11-30 2006-05-30 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
JP4035052B2 (ja) 2000-12-28 2008-01-16 キッセイ薬品工業株式会社 グルコピラノシルオキシピラゾール誘導体及びその医薬用途
CN1307190C (zh) 2002-03-22 2007-03-28 橘生药品工业株式会社 吡喃葡糖基氧代苄基苯衍生物的晶体
DE10231370B4 (de) 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
ES2567571T3 (es) 2003-03-14 2016-04-25 Astellas Pharma Inc. Derivados de C-glucósido y sales de los mismos
KR100942622B1 (ko) 2003-08-01 2010-02-17 미쓰비시 타나베 파마 코퍼레이션 나트륨-의존성 수송체에 대해 저해 활성을 갖는 신규화합물
EP2360164A3 (de) 2004-03-16 2012-01-04 Boehringer Ingelheim International GmbH Glucopyranosyl-substituierte Benzol-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
TW200637839A (en) 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
EP1989191B1 (en) 2006-02-15 2011-07-20 Boehringer Ingelheim International GmbH Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
JP5230613B2 (ja) 2006-05-23 2013-07-10 テラコス・インコーポレイテッド グルコース輸送体阻害剤およびその使用方法
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
WO2008109591A1 (en) 2007-03-08 2008-09-12 Lexicon Pharmaceuticals, Inc. Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
TW200904405A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
PT2183263E (pt) 2007-07-26 2012-01-11 Lexicon Pharmaceuticals Inc Processos e compostos úteis na preparação de inibidores do co-transportador 2 de glucose e sódio
WO2009035969A1 (en) 2007-09-10 2009-03-19 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of sglt
CN101917845A (zh) 2007-11-21 2010-12-15 法马克西斯制药公司 Ssao/vap-1的卤代烯丙胺抑制剂及其用途
TW201011043A (en) 2008-06-20 2010-03-16 Chugai Pharmaceutical Co Ltd Crystal of spiroketal derivatives and process for preparation of spiroketal derivatives
TWI472521B (zh) 2008-07-17 2015-02-11 Lexicon Pharmaceuticals Inc （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法
CN102149717B (zh) 2008-08-28 2014-05-14 辉瑞大药厂 二氧杂-双环[3.2.1]辛烷-2，3，4-三醇衍生物
KR101921934B1 (ko) 2009-02-13 2018-11-26 베링거 인겔하임 인터내셔날 게엠베하 글루코피라노실 디페닐메탄 유도체를 포함하는 약제학적 조성물, 이들의 약제학적 용량형, 이들의 제조방법 및 환자에서의 개선된 당 조절을 위한 이들의 용도
PT2601949E (pt) 2009-04-16 2014-11-12 Taisho Pharmaceutical Co Ltd Composições farmacêuticas com (1s)-1,5-anidro-1-[5-(4- etoxibenzil)-2-metoxi-4-metilfenil]-1-tio-d-glucitol e um secretagogo de insulina
PH12012500633B1 (en) 2009-09-30 2017-12-13 Boehringer Ingelheim Int Method for the preparation of a crystalline form of 1-chloro -4- (beta -d- glucopyranos -1-yl) -2- (4-((s)- tetrahydrofuran -3- yloxy) benzyl) benzene
WO2011039108A2 (en) 2009-09-30 2011-04-07 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
CA3086105A1 (en) * 2012-05-02 2013-11-07 Boehringer Ingelheim International Gmbh Substituted 3-haloallylamine inhibitors of ssao and uses thereof

Also Published As

Publication number Publication date
PH12019500845A1 (en) 2019-12-02
CN109843279A (zh) 2019-06-04
EP3528800A1 (en) 2019-08-28
US20210212968A1 (en) 2021-07-15
KR20190070956A (ko) 2019-06-21
EA201990951A1 (ru) 2019-11-29
WO2018073154A1 (en) 2018-04-26
JP2019531320A (ja) 2019-10-31
BR112019005930A2 (pt) 2019-06-11
CA3041169A1 (en) 2018-04-26
IL265989A (en) 2019-06-30
MX2019004549A (es) 2019-06-12
AU2017344882A1 (en) 2019-03-28

Similar Documents

Publication Publication Date Title
CL2019000935A1 (es) Composición farmacéutica, métodos para tratamiento y usos de la misma.
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CO2019013707A2 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson
EP3735976A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
PH12019500494A1 (en) Formulations of (r)-2-amino-3-phenylpropyl carbamate
MX383164B (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
MX2018004515A (es) Agentes de anticuerpo especificos para cd19 humano y usos de los mismos.
MX2019000965A (es) Composiciones y metodos para inihibir la masp-3 para el tratamiento de diferentes enfermedades y trastornos.
MX2017016655A (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
CL2019003670A1 (es) Composición que comprende manosa oligosacárido y proceso para realizarla y uso de esta.
BR112018005905A2 (pt) ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto?
MX2016011667A (es) Composiciones topicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad.
MX2023010501A (es) Profarmacos de dantroleno y metodos de su uso.
MX2018005825A (es) Celulas inmunes modificadas y usos de las mismas.
MX374705B (es) Composiciones que comprenden anakinra.
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
MX2018007128A (es) Composiciones para barnices dentales y metodos para su elaboracion y uso.
MX2021011334A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
EP3881845A3 (en) Combination of trazodone and gabapentin for the treatment of pain
MX384394B (es) Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas.
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
CL2018002930A1 (es) (+)-azasetron para uso en el tratamiento de desórdenes de oído.
UY37316A (es) Dispersión sólida farmacéutica de un inhibidor de bcl-2, composiciones farmacéuticas de ésta, y usos para el tratamiento de cáncer